The current study was performed as part of a clinical trial investigating the target engagement of a novel GLP1/glucagon receptor dual agonist, SAR425899, in individuals with T2D (clinicaltrials.gov identifier NCT03350191) (12). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.